UCL Business works closely with Professor Pete Coffey at the UCL Institute of Ophthalmology and Dire
29 September 2008
The London Project to Cure AMD (Age-Related Macular Degeneration) will develop a surgical therapy to stabilise and restore vision in people who go blind due to faulty retinal cells. AMD affects around a quarter of people over the age of 60 in the UK, and 14 million people across Europe.
A groundbreaking surgical therapy capable of stabilising and restoring vision in the vast majority of patients who currently suffer blindness through Age-Related Macular Degeneration (AMD) is to be taken to clinical trial by scientists and clinicians at the UCL Institute of Ophthalmology, Moorfields Eye Hospital and the University of Sheffield. The therapy, using cells derived from human embryonic stem cells to replace the faulty retinal cells that cause AMD, will be developed by the London Project to Cure AMD, a collaborative project launched today bringing together some of the leading specialists in the field.
For the full story please see the UCL website